A Journal of Antibiotics review from Onaka's group surveys how natural peptide-modifying enzymes can work on designed and synthetic peptide libraries.
Recap by typeshit. Full story at BIOENGINEER.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
The American College of Obstetricians and Gynecologists has issued new guidance, and she walks CBS News viewers through what it means for patients.
The NEJM study of 2,339 people without diabetes also found less knee osteoarthritis pain and fewer sleep apnea events on the drug than on placebo.
Loading…